Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

Bionor Pharma reports data from phase I trial of Vacc-C5

Feb. 25, 2014

Bristol-Myers Squibb discloses new agents for HIV infection

Feb. 24, 2014

HIV vaccine obtains FDA orphan drug status for pediatric HIV/AIDS infection

Feb. 18, 2014

Sedia Biosciences receives phase II funding from NIH for HIV-1 assay

Feb. 13, 2014

New HIV integrase inhibitors patented by Merck & Co.

Feb. 12, 2014

Merck & Co. discloses new HIV prodrugs

Feb. 11, 2014

U.S. Navy approves phase I trial of Multikine in patients with HIV/HPV and perianal warts

Feb. 4, 2014

Burnet Institute receives grant to evaluate HIV test

Feb. 4, 2014

Merck & Co. discloses novel agents for HIV infection

Jan. 31, 2014

Researchers at ViiV Healthcare disclose novel agents for HIV infection

Jan. 30, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
GDE4 blockade promotes remyelination, study finds
BioWorld Science
Myelin is crucial for the correct functioning of nerve signaling and its loss is a feature of neurological disorders. The cells responsible for myelination in the...